Seroquel (Quetiapine) is a medication that was developed by AstraZeneca from 1992 through 1996. It received FDA approval in 1997 for the treatment of schizophrenia, and has since received approval to treat both acute mania and depressive phases of bipolar disorder. The drug is classified as an atypical, second-generation antipsychotic and exerts pharmacological effects via …
Abilify (Aripiprazole) is a medication that was developed by Otsuka Pharmaceuticals and approved by the FDA in 2002 for the treatment of schizophrenia. Approximately 2 years thereafter (in 2004) it was approved for the treatment of acute mania and mixed episodes associated with bipolar disorder. By 2007, it had attained approval for the treatment of …
Vraylar (Cariprazine) was approved by the FDA on September 17, 2015 for the treatment of schizophrenia and mania associated with bipolar disorder. In clinical trials, the drug was referenced as “RGH-188” – containing Cariprazine as the primary active ingredient. The drug had completed Phase III clinical trials in 2012, and was pending FDA approval for …
Bipolar disorder is a condition characterized by cyclical mood swings, transitioning from depression to mania (or hypomania). For a period of time, an individual with bipolar disorder will experience debilitating bouts of depression – and often unexpectedly, their entire neurophysiology will shift to facilitate a state of mania (elevated mood). Diagnostically, there are multiple types …
It is estimated that over 2.5 million adults in the United States have been diagnosed with schizophrenia; this equates to approximately 1.1% of the population. There are many different types of schizophrenia, in fact, genetic clusters suggest it is 8 distinct diseases. Therefore not everyone diagnosed with schizophrenia has the same set of symptoms. Certain …
Invega (Paliperidone) is considered a newer spin-off of the antipsychotic Risperdal in that it contains the same active metabolite, but is thought to have fewer side effects and drug interactions. It was initially approved in 2006 for the treatment of schizophrenia and was since granted approval for the treatment of schizoaffective disorder in 2009. While …
Invega (Paliperidone) is an atypical antipsychotic approved in 2006 for the treatment of schizophrenia. Several years later in 2009, a longer-acting format of the medication called “Invega Sustenna” was also approved. Invega Sustenna is an injectable form of the drug that is administered every 4 weeks and is thought to be advantageous it mitigates risk …